List of Excipients in Branded Drug CIDOFOVIR DIHYDRATE

Generic Drugs Containing CIDOFOVIR DIHYDRATE

Company	Ingredient	NDC	Excipient
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	cidofovir dihydrate	23155-216	HYDROCHLORIC ACID
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	cidofovir dihydrate	23155-216	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in CIDOFOVIR DIHYDRATE?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE

Cidofovir Dihydrate Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Cidofovir dihydrate has limited commercial protection as an active pharmaceutical ingredient, but it retains formulation value in topical, ophthalmic, inhaled, and potentially localized delivery systems. The main commercial problem is cidofovir’s dose-limiting nephrotoxicity, poor oral bioavailability, and dependence on intravenous administration with probenecid and hydration. Excipient innovation is most valuable when it reduces systemic exposure, improves tissue delivery, extends shelf life, or enables a new regulatory pathway.

What is the approved cidofovir formulation?

Cidofovir is an acyclic nucleoside phosphonate antiviral. The U.S. reference product, Vistide, is an intravenous concentrate containing cidofovir at 75 mg/mL.

Attribute	Vistide profile
Active ingredient	Cidofovir
Salt form	Cidofovir dihydrate used as the drug substance designation
Dosage form	Intravenous injection concentrate
Strength	75 mg/mL
Pack size	375 mg in 5 mL
Key excipient	Sodium citrate
Vehicle	Water for injection
pH control	Hydrochloric acid and sodium hydroxide
Approved indication	CMV retinitis in adults with AIDS and adequate renal function
Administration requirement	Intravenous infusion after dilution
Renal-protection regimen	Probenecid and intravenous saline hydration

The formulation is relatively simple. Vistide contains sodium citrate as a buffering agent and uses pH adjustment to maintain product stability and tolerability. The central formulation burden does not arise from a complex excipient system. It arises from cidofovir’s pharmacology, particularly accumulation in renal tubular cells and nephrotoxicity at therapeutic systemic exposures. [1]

What excipient functions are most important for cidofovir?

The most important excipient functions are pH control, osmolality management, chemical stability, tissue retention, and controlled release.

Buffering and pH control

Cidofovir is a phosphonate with multiple ionizable groups. Its aqueous formulation requires control of pH and ionic strength to maintain solubility and limit degradation. Citrate is used in the reference product as the primary buffer system.

A development program should evaluate:

• Citrate concentration and buffer capacity
• Phosphate and acetate alternatives
• pH-dependent solubility
• Freeze-thaw stability
• Container-closure compatibility
• Precipitation after dilution into infusion fluids
• Compatibility with saline hydration protocols

A substitute buffer may create differentiation, but it also creates regulatory comparability risk. A reformulated injectable product would need to establish assay, impurities, particulate matter, sterility, endotoxin, extractables and leachables, and in-use stability.

Tonicity and infusion tolerability

Vistide is diluted before administration. Excipients should not increase the risk of hemolysis, infusion-site irritation, or precipitation during dilution. Hypertonic concentrates can be practical when diluted under controlled conditions, but direct administration is unsuitable.

Commercial opportunity exists in a ready-to-use or lower-concentration presentation that reduces pharmacy manipulation. The value would depend on whether the new presentation decreases preparation errors, shortens administration time, or improves outpatient use.

Solubilization

Cidofovir is sufficiently water-soluble for the approved intravenous product. Solubilizers are therefore less important for the existing indication than they are for alternative dosage forms.

For topical, ocular, or inhaled products, solubilizers may affect mucosal tolerability. Surfactants, cyclodextrins, and polyols should be screened cautiously because local toxicity can erase the benefit of localized delivery.

Preservatives

A multidose product could create commercial convenience, but preservatives may be poorly suited to ophthalmic, intralesional, or mucosal administration. A preservative-free single-dose format is more consistent with high-risk local administration and reduces concerns about benzalkonium chloride or other preservative-induced tissue injury.

What formulations are protected or commercially differentiated for cidofovir?

The strongest formulation opportunities are dosage forms that change exposure rather than merely replace citrate with another buffer.

Topical cidofovir

Topical cidofovir has been investigated and used in compounded preparations for viral skin disease, including molluscum contagiosum, human papillomavirus-associated lesions, and other cutaneous infections. Compounded products have included creams, gels, and solutions, but these uses do not establish the same regulatory status as an FDA-approved commercial product.

Potential excipient platforms include:

Platform	Commercial purpose	Principal development issue
Hydrogel	Lesion retention and controlled release	Cidofovir release and local irritation
Emulsion cream	Penetration into keratinized tissue	Phase separation and variable delivery
Mucoadhesive gel	Longer residence time	Local tolerability and patient acceptability
Film-forming solution	Occlusion and reduced dosing frequency	Drying, adhesion, and dose uniformity
Thermoresponsive gel	In situ retention	Manufacturing complexity
Nanoparticle suspension	Cellular or tissue targeting	CMC and safety burden

Topical products have the clearest excipient-led opportunity because they can reduce systemic exposure. The formulation must demonstrate consistent delivery into the target lesion without unacceptable skin or mucosal toxicity.

Ophthalmic cidofovir

Cidofovir’s approved use is systemic treatment of CMV retinitis. Local ophthalmic delivery could theoretically reduce renal exposure, but ocular administration creates demanding requirements for sterility, preservative selection, osmolality, pH, particle control, and ocular tolerability.

Potential formats include:

• Preservative-free solution
• In situ gelling drops
• Intravitreal depot
• Ocular implant
• Liposomal or polymeric particulate delivery

An ophthalmic product would likely be a new drug product rather than a simple generic substitution. If the route, dose, or indication changes materially, the sponsor would face a new clinical and CMC package.

Inhaled cidofovir

Inhaled delivery could target respiratory viral infections while limiting systemic exposure. Formulation candidates include nebulized solutions, dry powders, and spray-dried particles.

The major technical issues are:

• Aerosol particle-size distribution
• Delivered dose uniformity
• Pulmonary tolerability
• Device compatibility
• Hygroscopicity
• Powder dispersibility
• Local antiviral concentration
• Renal exposure after pulmonary absorption

Inhaled cidofovir is commercially distinct from brincidofovir, an orally active lipid-conjugated cidofovir derivative. Brincidofovir’s improved oral delivery reflects chemical modification of the active molecule, not an excipient-only strategy. [2]

Extended-release and depot products

Polymeric microspheres, implants, and injectable depots could maintain local exposure while reducing dosing frequency. The commercial case is strongest for chronic or recurrent localized viral disease.

The main barriers are substantial:

• High drug loading may be difficult
• Acidic polymer degradation can affect cidofovir stability
• Release rates may be difficult to control
• Residual solvents and degradation products require characterization
• Local tissue toxicity could limit dose
• The product may be treated as a complex drug-device or combination product

How does cidofovir compare with brincidofovir?

Brincidofovir is the principal product-level comparator for cidofovir delivery strategy. It uses a lipid conjugate to improve oral absorption and intracellular delivery. It is not an excipient reformulation of cidofovir.

Attribute	Cidofovir	Brincidofovir
Delivery concept	Direct phosphonate administration	Lipid-conjugated prodrug
Approved product history	Vistide intravenous injection	Tembexa oral tablets and suspension
Main toxicity concern	Nephrotoxicity	Different safety profile; gastrointestinal and hepatic monitoring remain relevant
Excipient opportunity	Localized delivery and depot systems	Oral suspension, tablet, and lifecycle formulations
Regulatory strategy	Reformulation or new dosage form	Separate active pharmaceutical ingredient and product estate
Generic competition	Historically high risk due to aged product	Patent and regulatory status depend on product and jurisdiction

For a formulation investor, cidofovir offers a lower active-ingredient barrier but a higher clinical differentiation burden. Brincidofovir offers stronger product differentiation but a more complex active-ingredient and patent position.

When did cidofovir lose market exclusivity?

Cidofovir’s original U.S. regulatory exclusivity expired many years ago. Vistide was approved by the FDA in 1996, and the product’s orphan-drug exclusivity period also expired long before the current market.

The commercial implications are direct:

• No meaningful remaining new-drug exclusivity protects the original Vistide concept.
• Any remaining protection would need to arise from later patents, formulation claims, manufacturing claims, device claims, or regulatory exclusivity for a new product.
• A sponsor cannot rely on the age of the active ingredient alone to obtain market protection.
• A new topical, inhaled, ophthalmic, or depot product could obtain independent patent and regulatory protection if it demonstrates a distinct product profile.

What is the Orange Book status of cidofovir?

The Orange Book is relevant to the approved Vistide product and any listed patents associated with that product. The original product’s exclusivity is expired, and cidofovir is not positioned like a recently approved small molecule with an active five-year new chemical entity period.

A generic applicant seeking approval for an equivalent intravenous product would generally assess:

1. Whether Vistide remains the listed reference product.
2. Whether any patents remain listed in the Orange Book.
3. Whether those patents are expired, delisted, or otherwise unenforceable.
4. Whether the proposed product is therapeutically equivalent.
5. Whether labeling can include the same renal-protection and administration requirements.

A reformulated product would not necessarily fit the conventional ANDA pathway. A different route, dosage form, concentration, or indication may require a 505(b)(2) application or a full new drug application, depending on the product design and reliance strategy. [3]

Are there Paragraph IV challenges or cidofovir litigation?

Cidofovir has no widely recognized current Paragraph IV litigation profile comparable to major revenue-generating small molecules. The commercial risk is primarily generic erosion of the legacy intravenous product and competition from compounded or off-label formulations, not an active branded patent dispute.

For a new cidofovir product, litigation risk would shift to:

• Formulation patents
• Local-delivery claims
• Dose and dosing-interval claims
• Combination claims with probenecid or hydration
• Device patents
• Manufacturing and particle-engineering claims
• Patent term adjustment and patent term extension calculations

A sponsor should avoid relying solely on a broad claim to "cidofovir in a topical formulation." Such claims can face validity challenges based on known cidofovir use in compounded topical products. Stronger protection would combine defined excipient ranges, release profiles, tissue concentrations, stability parameters, and clinically demonstrated outcomes.

How strong is the cidofovir patent estate?

The legacy patent estate is weak as a basis for protecting the original intravenous product because the active ingredient and original product have been marketed for decades. The stronger opportunity is a newly engineered product estate.

Patentable formulation elements

Potential claim categories include:

• Specific citrate or alternative-buffer concentrations
• Defined pH and osmolality ranges
• Preservative-free multidose or single-dose presentations
• Particle-size distributions for inhaled delivery
• Polymer composition and release kinetics
• Mucoadhesive excipient systems
• Ocular depot compositions
• Stabilized lyophilized products
• Container-closure systems
• Device-formulation combinations
• Methods that reduce renal exposure
• Local treatment regimens supported by pharmacokinetic data

Patent strength will depend on unexpected results. A patent application that only substitutes one conventional buffer for another is vulnerable to obviousness arguments. A formulation that provides a documented reduction in systemic exposure, longer lesion residence, improved adherence, or improved stability has a stronger commercial position.

What manufacturing barriers affect cidofovir formulation opportunities?

Manufacturing barriers differ by dosage form.

For injectable products, the main requirements are sterile manufacturing, control of particulate matter, validated aseptic processing, and reliable dilution stability. A ready-to-use presentation may require more container volume and higher shipping cost.

For topical products, the critical controls are drug uniformity, viscosity, microbial limits, preservative effectiveness where applicable, and drug release through the intended substrate.

For inhaled products, the major controls are emitted dose, aerodynamic particle-size distribution, moisture content, powder flow, device reproducibility, and dose-counter performance.

For depot products, the sponsor must control polymer molecular weight, residual solvents, drug loading, burst release, and degradation products.

The active ingredient is not the main manufacturing bottleneck. Product-specific control strategy is.

Which commercial opportunities are most attractive?

Highest-priority opportunity: topical prescription product

A topical product has the best balance between formulation differentiation, manageable manufacturing, and reduced systemic exposure. The target markets could include viral skin disease and selected mucosal infections, subject to clinical validation and regulatory approval.

Second priority: preservative-free ophthalmic product

An ophthalmic product could command premium pricing if it demonstrates meaningful benefit over compounded therapy. Sterility, ocular tolerability, and clinical efficacy create a higher development barrier.

Third priority: inhaled antiviral

An inhaled formulation could address respiratory viral disease, but the clinical opportunity depends on the pathogen, timing of treatment, and achievable pulmonary exposure. Device development raises cost and regulatory complexity.

Lower-priority opportunity: reformulated intravenous product

A simpler IV presentation could reduce preparation burden, but it would face generic competition and limited pricing power. The business case requires a clear hospital-pharmacy advantage.

What generic launch risks exist for cidofovir?

Generic entry risk is high for the legacy intravenous product because:

• The active ingredient is old.
• Original exclusivity has expired.
• The formulation is relatively simple.
• The clinical indication is established.
• A generic sponsor can target the same route and strength.
• Formulation differentiation may not justify a premium.

The main limitations are market size, nephrotoxicity, probenecid coadministration, and the narrow approved indication. These factors may reduce the incentive for multiple generic entrants, but they do not create durable IP protection.

Key Takeaways

• Vistide is a 75 mg/mL intravenous cidofovir formulation buffered with sodium citrate.
• Cidofovir’s principal product problem is nephrotoxicity, not aqueous solubility.
• Topical, ophthalmic, and inhaled delivery offer the strongest excipient-led opportunities.
• Brincidofovir is a chemically modified prodrug, not an excipient reformulation of cidofovir.
• The original cidofovir exclusivity period expired long ago.
• The legacy IV product has limited strategic patent value unless supported by later product-specific claims.
• Stronger new patents should protect measurable performance, including local exposure, release control, stability, or reduced systemic toxicity.
• A new route or dosage form may require a 505(b)(2) or full NDA pathway rather than a conventional ANDA.
• Generic risk for the legacy IV product is high, while commercial opportunity depends on differentiated delivery and a clinically relevant indication.

FAQs

Can sodium citrate be replaced in a cidofovir formulation?

Yes, but the replacement would require comparative stability, solubility, compatibility, and safety data. A buffer substitution alone is unlikely to create strong market protection without an unexpected technical benefit.

Is cidofovir suitable for oral formulation development?

Unmodified cidofovir has poor oral delivery characteristics and significant systemic toxicity concerns. Oral development is more closely associated with prodrug strategies such as brincidofovir than with conventional excipient optimization.

Can a compounded topical cidofovir product compete with a commercial formulation?

Yes. A commercial product would need to offer better dose uniformity, stability, convenience, tolerability, or clinical evidence than compounded preparations.

Does probenecid create an excipient opportunity?

Probenecid is a coadministered renal-protection medicine, not an excipient. A fixed-dose combination would create substantial regulatory, pharmacokinetic, and labeling complexity.

What is the most defensible cidofovir patent strategy?

The strongest strategy is a layered portfolio covering a defined delivery system, excipient composition, release profile, manufacturing process, device, and clinically supported dosing method.

References

1. U.S. Food and Drug Administration. (1996). Vistide (cidofovir injection) prescribing information.
2. U.S. Food and Drug Administration. (2021). Tembexa (brincidofovir) prescribing information.
3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. National Library of Medicine. (2024). Cidofovir: Drug information and labeling records. DailyMed.
5. National Center for Biotechnology Information. (2024). Cidofovir compound summary. PubChem.